Atreca General and Administrative Expenses 2011-2025 | BCEL

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Atreca

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
31.5 M	32 M	26.8 M	17.8 M	7.06 M	4.56 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
32 M	4.56 M	20 M

Quarterly General and Administrative Expenses Atreca

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
5.39 M	6.84 M	8.08 M	-	7.25 M	8.08 M	8.61 M	-	8.8 M	8.03 M	7.82 M	-	6.61 M	6.46 M	7.12 M	-	4.86 M	3.54 M	2.52 M	-	1.88 M	1.63 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
8.8 M	1.63 M	6.09 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Graybug Vision GRAY	22.2 M	$ 0.44	-11.23 %	$ 9.65 M	USA
AgeX Therapeutics AGE	9.33 M	$ 11.3	-10.17 %	$ 12.2 K	-
Galera Therapeutics GRTX	11 M	$ 0.14	-32.59 %	$ 7.61 M	USA
AnPac Bio-Medical Science Co., Ltd. ANPC	7.25 M	$ 4.37	-1.58 %	$ 28.1 M	China
Axon Enterprise AXON	741 M	$ 723.51	-1.19 %	$ 54.8 B	USA
Caladrius Biosciences CLBS	12.1 M	$ 0.43	-16.75 %	$ 25.8 M	USA
Sorrento Therapeutics SRNE	197 M	$ 0.27	-29.58 %	$ 126 M	USA
BeiGene, Ltd. BGNE	1.83 B	$ 184.71	0.49 %	$ 251 B	Cayman-islands
Heron Therapeutics HRTX	53.4 M	$ 1.2	3.02 %	$ 183 M	USA
ContraFect Corporation CFRX	12.2 M	$ 1.47	-5.16 %	$ 5.39 M	USA
Orchard Therapeutics plc ORTX	49.1 M	$ 4.93	1.02 %	$ 90.8 M	Britain
Midatech Pharma plc MTP	4.95 M	$ 0.29	-18.52 %	$ 27.3 M	Britain
Advaxis ADXS	12.2 M	$ 0.31	-9.65 %	$ 45.9 M	USA
Heat Biologics, Inc. HTBX	15 M	$ 3.93	-5.76 %	$ 99.8 M	USA
La Jolla Pharmaceutical Company LJPC	35.4 M	$ 6.2	-	$ 154 M	USA
Zymeworks ZYME	42.6 M	$ 6.42	-	$ 404 M	Canada
Aeterna Zentaris AEZS	5.92 M	$ 5.72	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	15.7 M	$ 10.5	-	$ 231 M	USA
Kadmon Holdings, Inc. KDMN	43.2 M	$ 9.5	-	$ 1.7 B	USA
BioDelivery Sciences International BDSI	106 M	$ 2.58	-4.8 %	$ 255 M	USA
Zosano Pharma Corporation ZSAN	10.5 M	$ 0.56	7.23 %	$ 2.72 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	$ 0.5	-	$ 7.46 M	Israel
Kiromic BioPharma KRBP	8.85 M	$ 3.15	6.61 %	$ 3.08 M	USA
Acceleron Pharma Inc. XLRN	56.5 M	$ 179.68	-	$ 10.9 B	USA
Albireo Pharma ALBO	69.6 M	$ 44.15	-0.23 %	$ 916 M	USA
Stealth BioTherapeutics Corp MITO	19.7 M	$ 0.32	-	$ 23.9 M	USA
Trillium Therapeutics Inc. TRIL	36.3 M	$ 18.44	-	$ 1.94 B	Canada
Kaleido Biosciences KLDO	21 M	$ 0.29	-3.69 %	$ 12.4 M	USA
Entasis Therapeutics Holdings ETTX	15.2 M	$ 2.19	-	$ 105 M	USA
Humanigen HGEN	15.6 M	$ 0.04	-81.12 %	$ 4.28 M	USA
Aptinyx APTX	19.8 M	$ 0.06	-39.0 %	$ 4.57 M	USA
Tyme Technologies TYME	10.2 M	$ 0.31	8.07 %	$ 54 M	USA
Forward Pharma A/S FWP	3.65 M	$ 2.64	-0.75 %	$ 18.7 M	Danmark
Applied Genetic Technologies Corporation AGTC	17 M	$ 0.39	-	$ 26.5 M	USA
Celyad Oncology SA CYAD	9.91 M	$ 0.47	-	$ 12.5 M	Belgium
Brickell Biotech BBI	11.2 M	$ 2.11	-5.38 %	$ 6.06 M	USA
Genocea Biosciences GNCA	14.7 M	$ 0.05	-15.0 %	$ 3.04 M	USA
Codiak BioSciences CDAK	27.6 M	$ 0.06	-55.98 %	$ 2.15 M	USA
Concert Pharmaceuticals CNCE	22.5 M	$ 8.37	-	$ 401 M	USA
AIkido Pharma AIKI	29.7 M	$ 3.17	1.93 %	$ 17.4 M	USA
Novo Nordisk A/S NVO	3.96 B	$ 49.14	-0.62 %	$ 421 B	Danmark
Calithera Biosciences CALA	20.9 M	$ 0.37	-10.95 %	$ 876 K	USA
Forma Therapeutics Holdings FMTX	48.3 M	$ 20.01	-	$ 958 M	USA
Oncolytics Biotech ONCY	5.36 M	$ 1.09	-8.58 %	$ 115 M	Canada
Arena Pharmaceuticals ARNA	126 M	$ 49.55	-6.81 %	$ 3.04 B	USA
ORIC Pharmaceuticals ORIC	28.8 M	$ 12.52	-4.86 %	$ 873 M	USA
Sierra Oncology SRRA	27.4 M	$ 54.89	-0.05 %	$ 1.34 B	Canada
Regulus Therapeutics RGLS	9.96 M	$ 8.16	-	$ 155 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Precigen PGEN	101 M	$ 4.17	0.72 %	$ 1.02 B	USA